Shree Ganesh Remedies Ltd
Shree Ganesh Remedies Q3 FY25: Revenue ₹27.05 Cr, PAT ₹5.43 Cr
Q3 FY25 investor presentation: what the company reported on revenue, margins and capex.
- Revenue
- ₹27Cr
- −3.3% YoY
- Net profit
- ₹5Cr
- +13.1% YoY
- Margin
- 36.64%
- +7.3 pp YoY
Guidance rank: #84 of 87 in Pharmaceuticals & Biotechnology
See the sector's top 10 — free with your mobile number.
Shree Ganesh Remedies Ltd Q3 FY25 key numbers
- Revenue
- Quarter-on-Quarter (QoQ) Revenue Change: -16% (from ₹32.33 Cr in Q2FY25).
As stated in Shree Ganesh Remedies Ltd's Q3 FY25 investor presentation · published 24 Sept 2026. Reported figures, not investment advice.
Based on Shree Ganesh Remedies Ltd's Q3 FY25 investor presentation. The company has not published an earnings-call transcript for this quarter, so figures here are what the investor presentation reports, not management guidance.
The short version
Q3FY25 Revenue from Operations: ₹27.05 Cr EBITDA for Q3FY25: ₹9.90 crore, up 21% YoY
From Shree Ganesh Remedies Ltd's Q3 FY25 earnings-call transcript · updated 24 Sept 2026.
Revenue & Sales Performance
- Q3FY25 Revenue from Operations: ₹27.05 Cr
- Q3FY24 Revenue from Operations: ₹27.97 Cr
- Year-on-Year (YoY) Revenue Change: -3%
- Quarter-on-Quarter (QoQ) Revenue Change: -16% (from ₹32.33 Cr in Q2FY25)
- 9 Months FY25 Revenue: ₹84.16 Cr vs. ₹88.11 Cr in 9MFY24, a -4% YoY change
- Volume Outlook:
- Management commentary notes a decline in revenue due to intensified competition and price reductions in traditional products despite volume growth.
- No volumetric growth expected in current quarter due to maintenance shutdown of Block 3.
2 more points from Shree Ganesh Remedies Ltd's call on revenue
Create a free account to keep reading this call
Profitability & Margins
See what Shree Ganesh Remedies Ltd said on profitability & margins — free account, 30 seconds.
Capital Expenditure Plans
- Ankleshwar site expansion with recently acquired 20,100 sq m land; total land now 36,500 sq m; CAPEX ₹26 crores for adjacent unit acquisition.
- Block 8 added in FY24 at Ankleshwar; CAPEX ₹15 crores; ramp-up progressing as planned; optimal capacity expected by early next financial year.
- Block 3 undergoing maintenance and refurbishment shutdown in current quarter; no volumetric growth expected this quarter due to this.
- Block 7 construction started; designed phase completed; expected completion by end Q4FY26; commercial production to start Q1FY27.
- Ample land for 4 more blocks (Blocks 7, 9, 10, 11) planned over coming years.
2 more points from Shree Ganesh Remedies Ltd's call on capex
Create a free account to keep reading this call
Top-ranked in Pharmaceuticals & Biotechnology
Ranked on what management guided this quarter
Rank buckets describe management commentary on revenue and margin. Not investment advice, and not a forecast of returns.
Fundraising & Capital Structure
See what Shree Ganesh Remedies Ltd said on fundraising & capital structure — free account, 30 seconds.
Order Book & Pipeline
See what Shree Ganesh Remedies Ltd said on order book & pipeline — free account, 30 seconds.
Shree Ganesh Remedies Ltd — Quarterly revenue & net profit
Shree Ganesh Remedies Ltd Q3 FY25 results — key figures
| ₹ Cr | Q3 FY25 | Q3 FY24 | YoY | Q2 FY25 | QoQ |
|---|---|---|---|---|---|
| Revenue | 27 | 28 | -3.3% | 32 | -16.3% |
| Operating profit (EBITDA) | 10 | 8 | +20.7% | 11 | -12.4% |
| Operating margin | 36.64% | 29.35% | +7.3 pp | 34.98% | +1.7 pp |
| Profit before tax | 8 | 7 | +1.6% | 9 | -12.8% |
| Net profit (PAT) | 5 | 5 | +13.1% | 6 | -15.4% |
| EPS (₹) | 4.23 | 3.75 | +12.8% | 5.00 | -15.4% |
Source: reported quarterly figures (Screener), ₹ crore.
Reported quarterly figures (₹ Cr). Latest (Q4 FY26): revenue ₹33 Cr, net profit ₹6 Cr. Revenue and profit are scaled separately — hover a quarter for exact figures.
Full financials →Continue your research
What Shree Ganesh Rem's management said in earlier quarters
- Q1 FY27 earnings call analysis →
- Q3 FY26 earnings call analysis →
- Q1 FY26 earnings call analysis →
- Q2 FY25 earnings call →
Earlier calls (1)
Others in Pharmaceuticals & Biotechnology this season
- SMS Pharmaceuticals (Q3 FY25)
Q3FY25 revenue from operations: ₹173.35 crore, up 7% YoY from ₹161.48 crore in Q3FY24 (Page 18, 5). Key concall takeaways from SMS Pharmaceuticals Ltd's Q3…
- Wockhardt (Q3 FY25)
725 crore, up 2% quarter-on-quarter and 2.2% year-on-year (Q3 FY24 revenue: Rs. Key concall takeaways from Wockhardt Ltd's Q3 FY25 earnings call — and how it…
- NGL Fine Chem (Q3 FY25)
Q3FY25 revenue from operations: ₹89.10 crores, a year-on-year (Y-o-Y) increase of 1.30% (Page 8). Key concall takeaways from NGL Fine Chem Ltd's Q3 FY25…
- Themis Medicare (Q3 FY25)
93.81 Cr, a 13.69% year-on-year (YoY) increase from Rs. Key concall takeaways from Themis Medicare Ltd's Q3 FY25 earnings call — and how it ranks against…
Potential multibaggers · Q2 FY27
Potential multibaggers in Pharmaceuticals & Biotechnology
on management's own guidance
- Strong growth2
- Strong growth1
- Strong growth3
Portfolio builder
Build your portfolio
from the top-ranked stocks
- 1. Pick 3–15 stocks
- 2. Choose large, mid or small cap and your sectors
- 3. Get a portfolio built from the rankings
Ranks describe management commentary on revenue and margin from the latest earnings call. Not investment advice.
Arthneeti Pro · Annual
Shree Ganesh Remedies Ltd and 15K+ more earnings calls,
for less than your morning chai
a day
Every earnings call, ranking and concall Q&A across all four results seasons.
Secure Razorpay payment · instant access
Frequently Asked Questions
What were Shree Ganesh Remedies Ltd Q3 FY25 results?
Q3FY25 Revenue from Operations: ₹27.05 Cr EBITDA for Q3FY25: ₹9.90 crore, up 21% YoY
What is Shree Ganesh Remedies Ltd share price analysis?
Shree Ganesh Remedies Ltd currently shows a neutral. The stock trades at a P/E of 58.0 with a market cap of ₹896 Cr. Investors should review the full earnings analysis for detailed insights.
Is Shree Ganesh Remedies Ltd planning capital expenditure?
Ankleshwar site expansion with recently acquired 20,100 sq m land; total land now 36,500 sq m; CAPEX ₹26 crores for adjacent unit acquisition.
Keep Shree Ganesh Remedies Ltd on your radar — track it to get its next earnings analysis in your feed.
This analysis is AI-generated based on publicly available earnings data and the company's investor presentation. This is not investment advice. Please consult a SEBI-registered advisor before making investment decisions.